BCL2 and acute myeloid leukemia: In the THP-1 model of acute myeloid leukemia (AML), neither the Bcl-2 inhibitor venetoclax nor cytarabine showed appreciable single-agent efficacy (Fig. 4e) closely resembling the clinical experience in refractory AML patients51.